COSMOS Registry for CytoSorb Therapy in Critically Ill Patients
Author Information
Author(s): Mavragani Amaryllis, Putzu Alessandro, Hui Wun Fung, Fumeaux Thierry, Taccone Fabio Silvio, Brunkhorst Frank Martin, Bottari Gabriella, Hidalgo Jorge, Kribben Andreas, Teboul Jean-Louis, Tomescu Dana, Klaus Teresa, Scheier Joerg, Deliargyris Efthymios, Ferrer Ricard
Primary Institution: Vall d'Hebron University Hospital
Hypothesis
The COSMOS registry aims to assess the effects of CytoSorb therapy on critically ill patients in real-world settings.
Conclusion
The COSMOS registry will provide valuable data on patient outcomes with CytoSorb therapy, helping to optimize treatment practices.
Supporting Evidence
- The registry started enrolling patients on July 15, 2022.
- It aims to collect data from multiple countries including Germany, Spain, Portugal, and Italy.
- An initial readout of the data is planned for presentation at an international conference in 2024.
- The registry will help refine best practices for CytoSorb therapy.
- Data will be collected at various time points including baseline, during therapy, and at discharge.
Takeaway
This study is like a big notebook where doctors write down how well a special treatment works for very sick patients, so they can help more people in the future.
Methodology
The registry collects prospective data from patients treated with CytoSorb during routine care across multiple countries.
Potential Biases
There may be risks of bias due to the observational nature of the study and the variability in treatment practices.
Limitations
The registry may not capture all variables affecting patient outcomes, and there is a potential for selection bias.
Participant Demographics
Critically ill patients, including children, receiving CytoSorb therapy.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website